ResMed nominates new director

ResMed (ASX:RMD) has nominated US healthcare professional Carol J Burt for an open position on its board of directors.

Shareholders in the sleep-disordered breathing technology company will vote on whether to appoint Burt to the board at the company’s AGM on 14 November.

Burt is a principal of Burt-Hillard Investments, a private investment and consulting firm targeting the healthcare industry. She has previously held roles including senior vice president of corporate finance and development for health benefits company WellPoint.

ResMed CEO Mick Farrell said if appointed, Burt will play a key role in helping to guide the company’s future.

“Government and private health care payers are beginning to realise the significant benefits of proactively treating sleep-disordered breathing among their covered lives,” he said.

“Reducing costs associated with treatment of chronic conditions such as hypertension and heart failure is escalating as a priority in care management. With Ms Burt’s guidance, we’d like to accelerate that escalation.”

If appointed, Burt will be replacing Michael Quinn, a 21-year veteran of the ResMed board who will not be standing for re-election.

ResMed has separately announced that it will release its September-quarter financial results on 24 October.

ResMed (ASX:RMD) shares were trading 0.79% lower at $5.685 as of around 1 pm on Friday.